Prescient Therapeutics Lands 30-Year Oncology Veteran as CMO Ahead of Phase 2 Data
Prescient Therapeutics has appointed Dr Rosalind Wilson as Chief Medical Officer, effective 13 July 2026. Dr Wilson brings more than 30 years of experience in clinical development, regulatory strategy, and executive leadership to the role. The appointment strengthens Prescient’s leadership team as the company advances its clinical programmes, including the ongoing Phase 2 study of PTX-100 in Cutaneous T-cell lymphoma (CTCL).
Prescient Therapeutics appoints Dr Rosalind Wilson as Chief Medical Officer
Dr Wilson joins Prescient at a pivotal stage as the company progresses its lead asset, PTX-100, through global Phase 2 recruitment. Her appointment follows the decision of outgoing CMO Dr Marissa Lim to step back from full-time employment and move into semi-retirement. Dr Lim contributed significantly to the progression of Prescient’s clinical programmes during her tenure.
The timing of Dr Wilson’s appointment is strategically significant. With the Phase 2 CTCL study recruiting globally and targeting enrolment of up to 40 patients in the Phase 2a cohort, the company is entering a critical execution phase that will generate key clinical data. A CMO with Dr Wilson’s track record of advancing therapies through approval and commercialisation brings enhanced execution capability at a stage where clinical trial design, regulatory strategy, and data interpretation become increasingly important.
CEO James McDonnell stated: “We are delighted to welcome Dr Rosalind Wilson to Prescient. Ros brings an exceptional track record in oncology drug development and executive leadership, with deep experience advancing therapies through to approval and commercialisation. Her expertise will be instrumental as we progress our pipeline and deliver on our next phase of growth.”
When big ASX news breaks, our subscribers know first
Dr Wilson’s career highlights and oncology development expertise
Dr Wilson’s career spans senior global leadership roles across biotechnology and pharmaceutical companies. Her experience includes:
- Global Head of Drug Development at Telix Pharmaceuticals
- CEO of ASX-listed Factor Therapeutics
- Previous Chief Medical Officer roles at oncology-focused biotechnology companies
Earlier in her career, Dr Wilson led the global development and launch strategy for pertuzumab (Perjeta) at Roche. She contributed to accelerating approval timelines and landmark regulatory precedents in breast cancer.
Her experience covers the full drug development continuum, from Phase 1 studies through to regulatory submission and commercial launch, across multiple oncology indications. This end-to-end expertise is directly relevant to Prescient’s goal of progressing PTX-100 beyond Phase 2 and towards potential regulatory approval.
What does a Chief Medical Officer do at a clinical-stage biotech?
For readers less familiar with biotechnology roles, the Chief Medical Officer is a critical position at clinical-stage companies. The CMO leads the design, execution, and oversight of clinical trials that test whether a drug is safe and effective in patients. This includes determining how trials should be structured, which patients should be enrolled, what endpoints should be measured, and how data should be interpreted.
The CMO also shapes regulatory strategy, deciding which approval pathways to pursue and how to engage with regulators such as the US FDA and other global authorities. For Prescient, Dr Wilson will lead clinical development strategy and execution, including the advancement of PTX-100 in its Phase 2 CTCL study and progression of the broader pipeline.
At a clinical-stage company, the CMO directly influences trial success, regulatory timelines, and ultimately the pathway to potential commercialisation. With PTX-100 already benefiting from US FDA Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for relapsed or refractory mycosis fungoides, Dr Wilson’s regulatory expertise positions her to capitalise on these designations and potentially accelerate the development timeline.
PTX-100 Phase 2 study and Prescient’s pipeline focus
PTX-100 is a first-in-class compound that blocks geranylgeranyl transferase-1 (GGTase-1), an enzyme involved in cancer cell growth. It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac, and Ral circuits in cancer cells, leading to cancer cell death. PTX-100 is understood to be the only GGTase-1 inhibitor in clinical development globally.
The drug demonstrated safety and early clinical activity in a previous Phase 1 study and a recent pharmacokinetic/pharmacodynamic basket study of haematological and solid malignancies. It recently completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The current Phase 2 study in CTCL is recruiting globally and expects to enrol up to 40 patients in the Phase 2a portion of the trial.
PTX-100 has been granted US FDA Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of CTCL.
Beyond PTX-100, Prescient is developing a suite of cell therapy enhancement platforms. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. CellPryme-A is an adjuvant therapy designed to help patients overcome a suppressive tumour microenvironment. CellPryme-M is a manufacturing enhancement technology that shifts T cells towards a central memory phenotype, improving persistence and tumour penetration. All three platforms are in pre-clinical or development stages.
| Asset | Stage | Key Status |
|---|---|---|
| PTX-100 | Phase 2 | CTCL study recruiting globally; up to 40 patients in Phase 2a; FDA Orphan Drug & Fast Track Designations |
| OmniCAR | Pre-clinical | Universal immune receptor platform for controllable T-cell activity |
| CellPryme-A | Pre-clinical | Adjuvant therapy to overcome suppressive tumour microenvironment |
| CellPryme-M | Pre-clinical | Manufacturing enhancement for improved T-cell persistence and potency |
Management commentary on the appointment
Dr Wilson commented on her appointment, highlighting the opportunity to deliver patient benefit at a critical stage of the company’s development:
Dr Rosalind Wilson, Chief Medical Officer
“I am excited to join Prescient at such an important stage in its development. The Company’s pipeline represents a compelling opportunity to deliver meaningful benefit to patients with cancer. I look forward to working with the team to advance these programmes and unlock their full potential.”
CEO James McDonnell also acknowledged the contribution of outgoing CMO Dr Marissa Lim: “We thank Dr Marissa Lim for her valuable contributions to Prescient and wish her well in her next chapter.”
The next major ASX story will hit our subscribers first
Investor briefing details
Prescient will hold an online investor briefing on Monday, 29 June 2026 at 11am AEST. CEO James McDonnell will provide an overview of the company’s progress and the strategic rationale for the leadership appointment. Investors can register for the briefing at: https://prescienttherapeutics.investorportal.com.au/investor-briefing/
The briefing provides an opportunity for investors to hear directly from management about the company’s clinical development plans and strategic priorities as it enters this next phase of growth. Direct engagement with leadership is particularly valuable during periods of transition, allowing investors to assess the company’s strategic direction and execution capability firsthand.
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX healthcare announcements delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to stay ahead on clinical trial updates, regulatory milestones, and leadership appointments the moment they break.